Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Empagliflozin has received both FDA approval and support from major regulatory bodies for its use in adults with chronic kidney disease (CKD) to reduce the risk of kidney disease progression, end-stage kidney disease, cardiovascular death, and hospitalization. This approval is based on extensive evidence, notably from the EMPA-KIDNEY trial, which demonstrated clinically significant benefits for patients with CKD, irrespective of diabetes status.
…